Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3143753 · 1 trial · 1 indication
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| Arm | Type | Description |
|---|---|---|
| LY3143753 (Part A) | EXPERIMENTAL | Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1 |
| LY3185643 (Part B) | EXPERIMENTAL | Single SC injection of ascending doses of LY3185643 on Day 1 |
| Placebo (Part A) | PLACEBO_COMPARATOR | Single SC injection of normal saline on Day 1 |
| rGlucagon (Part B) | ACTIVE_COMPARATOR | Single SC injection on Day 1 |
| Placebo (Part B) | PLACEBO_COMPARATOR | Single SC injection of normal saline on Day 1 |
| Name | Type | Description |
|---|---|---|
| LY3143753 (Part A) | DRUG | Administered via SC injection |
| LY3185643 (Part B) | DRUG | Administered via SC injection |
| Placebo (Part A and Part B) | DRUG | Administered via SC injection |
| rGlucagon (Part B) | DRUG | Administered via SC injection |
Inclusion Criteria: * Overtly healthy males or females * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures Exclusion Criteria: * Are investigator site personnel directly affiliated with this study and their immediate fam...
LY3143753 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other, meaning it is not specifically tied to a major disease category at this stage.
LY3143753 is being studied for use in healthy participants. It is an investigational small molecule in Phase 1 clinical development. The drug has not been approved for any medical condition, and its intended therapeutic use has not been established beyond early-stage testing in healthy volunteers.
LY3143753 is developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker LLY. The drug is an investigational small molecule currently in Phase 1 clinical development, with studies conducted in healthy participants.
LY3143753 is in Phase 1 clinical development. It is an investigational small molecule, and it has not been approved by regulatory authorities. The drug is still in early-stage testing, with one completed Phase 1 trial involving healthy participants.
LY3143753 has been studied in one clinical trial, identified as NCT02342314, titled "A Study of LY3143753 and LY3185643 in Healthy Participants." This Phase 1 trial was completed and enrolled 68 participants in the United Kingdom. The study was randomized, double-blind, and placebo-controlled.
LY3143753 and LY3185643 are two separate investigational drugs that were studied together in the same clinical trial, NCT02342314. They are not the same drug. The trial was a Phase 1 study in healthy participants, and both are being developed by Eli Lilly and Company.